title: Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
abstract: The presentation of tumor antigen-derived peptides by human leukocyte antigen (HLA) class I surface antigens on tumor cells is a key prerequisite to trigger effective T-cell responses in cancer patients. Multiple complementary strategies like cDNA and serological expression cloning, reverse immunology and different 'ome'-based methods have been employed to identify potential T-cell targets. This report focuses on a ligandomic profiling approach leading to the identification of 49 naturally processed HLA class I peptide ligands presented on the cell surface of renal cell carcinoma (RCC) cells. The source proteins of the defined HLA ligands are classified according to their biological function and subcellular localization. Previously established cDNA microarray data of paired tissue specimen of RCC and renal epithelium assessed the transcriptional regulation for 28 source proteins. In addition, HLA-A2-restricted, peptide-specific T cells directed against a HLA ligand derived from sulfiredoxin-1 (SRXN1) were generated, which were able to recognize and lyse ligand-presenting target cells in a HLA class I-restricted manner. Furthermore, tumor-infiltrating T cells isolated from a RCC patient were also able to kill SRXN1 expressing tumor cells. Thus, this experimental strategy might be suited to define potential candidate biomarkers and novel targets for T-cell-based immunotherapies of this disease.
authors: Institute of Medical Immunology, Martin-Luther University Halle-Wittenberg, Halle, Germany. barbara.seliger@medizin.uni-halle.de
authors: Barbara
authors: B
authors: Seliger
authors: Sven P
authors: SP
authors: Dressler
authors: Chiara
authors: C
authors: Massa
authors: Christian V
authors: CV
authors: Recktenwald
authors: Florian
authors: F
authors: Altenberend
authors: Juergen
authors: J
authors: Bukur
authors: Francesco M
authors: FM
authors: Marincola
authors: Ena
authors: E
authors: Wang
authors: Stefan
authors: S
authors: Stevanovic
authors: Rudolf
authors: R
authors: Lichtenfels
references: Immunol Rev. 2002 Oct;188:22-32
references: 12445278
references: J Proteome Res. 2010 Jul 2;9(7):3710-9
references: 20455597
references: Mol Cell Proteomics. 2005 Dec;4(12):1920-32
references: 16127175
references: Cancer Immunol Immunother. 2009 Sep;58(9):1407-17
references: 19184600
references: Mol Cell Proteomics. 2009 Nov;8(11):2595-612
references: 19674965
references: Mol Cell Proteomics. 2009 Dec;8(12):2827-42
references: 19752005
references: Cancer Res. 1998 Dec 15;58(24):5803-11
references: 9865739
references: Contrib Nephrol. 2008;160:88-106
references: 18401164
references: Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4163-70
references: 16857787
references: Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19738-43
references: 19057013
references: Transl Oncol. 2010 Apr;3(2):65-79
references: 20360931
references: Annu Rev Med. 2010;61:329-43
references: 20059341
references: Biochem Biophys Res Commun. 2001 Dec 14;289(4):876-81
references: 11735128
references: Mol Cell Proteomics. 2007 Jan;6(1):102-13
references: 17074750
references: J Immunol. 2007 Jun 1;178(11):6923-30
references: 17513741
references: Annu Rev Immunol. 2002;20:463-93
references: 11861610
references: J Immunol. 2005 Mar 1;174(5):2544-51
references: 15728460
references: Anal Biochem. 1995 Mar 20;226(1):15-25
references: 7785766
references: Oncology. 2001;60(1):1-7
references: 11150901
references: Curr Opin Urol. 2009 Sep;19(5):441-6
references: 19584732
references: Eur J Immunol. 2008 Nov;38(11):2993-3003
references: 18991276
references: Curr Mol Med. 2001 Nov;1(5):609-19
references: 11899235
references: Nat Biotechnol. 2004 Apr;22(4):450-4
references: 15004565
references: J Proteome Res. 2006 Mar;5(3):651-8
references: 16512681
references: Proteomics. 2009 Mar;9(6):1567-81
references: 19235166
references: Cancer Res. 2008 Dec 15;68(24):10086-93
references: 19074874
references: Rapid Commun Mass Spectrom. 1996;10(8):889-96
references: 8777321
references: Proteomics. 2006 Jan;6(1):364-74
references: 16196104
references: Immunogenetics. 1985;21(3):235-46
references: 3872841
references: Biol Chem. 2009 Aug;390(8):783-94
references: 19426129
references: Proteomics. 2002 May;2(5):561-70
references: 11987130
references: Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3825-30
references: 18308940
references: Cell. 1978 May;14(1):9-20
references: 667938
references: Nat Immunol. 2003 Apr;4(4):375-9
references: 12598896
references: Cancer Immunol Immunother. 2005 Sep;54(9):826-36
references: 15627209
references: J Biol Chem. 2004 Dec 3;279(49):50994-1001
references: 15448164
references: Proteomics. 2008 Aug;8(15):3194-203
references: 18615424
references: Anal Chem. 2010 Mar 1;82(5):1584-8
references: 20121140
references: J Am Soc Mass Spectrom. 2004 Jun;15(6):803-22
references: 15144970
references: Proteomics. 2007 Dec;7(24):4601-12
references: 18072195
references: Cancer Biol Ther. 2005 Sep;4(9):943-8
references: 16082191
references: Mol Cell Proteomics. 2005 Dec;4(12):1888-97
references: 16112985
references: Crit Rev Immunol. 2007;27(5):485-93
references: 18197809
references: Science. 1992 Mar 6;255(5049):1261-3
references: 1546328
references: J Immunol. 2005 Mar 1;174(5):2763-9
references: 15728485
references: J Proteome Res. 2009 Jul;8(7):3666-74
references: 19415920
references: Immunity. 2003 Mar;18(3):429-40
references: 12648459
references: Immunity. 2003 Mar;18(3):343-54
references: 12648452
references: Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17107-12
references: 16286653
references: Cancer Res. 2003 Jul 15;63(14):4107-11
references: 12874014
references: Cancer Res. 2004 Oct 15;64(20):7279-87
references: 15492247
references: Mol Carcinog. 2009 Oct;48(10):886-94
references: 19263436
references: Immunogenetics. 1999 Nov;50(3-4):213-9
references: 10602881
references: Annu Rev Immunol. 1999;17:739-79
references: 10358773
references: Immunogenetics. 1998 Jul;48(2):156-60
references: 9634482
references: Mol Cell Proteomics. 2004 Mar;3(3):193-208
references: 14718575
references: Cancer Immunol Immunother. 2004 Mar;53(3):144-7
references: 14727084
references: Nature. 1991 May 23;351(6324):290-6
references: 1709722
references: Cytotherapy. 2002;4(4):317-27
references: 12396831
references: Mol Immunol. 2002 Oct;39(3-4):203-15
references: 12200051
references: Clin Cancer Res. 2010 Mar 1;16(5):1348-54
references: 20179240
references: Immunogenetics. 1999 Jun;49(6):571-6
references: 10380706
references: Nature. 2002 Oct 3;419(6906):480-3
references: 12368856
references: Cancer Res. 2002 Oct 15;62(20):5818-27
references: 12384544
references: Curr Pharm Des. 2009;15(28):3221-36
references: 19860672
references: Clin Cancer Res. 2007 Jun 1;13(11):3347-55
references: 17545542
references: J Immunol. 2009 Nov 1;183(9):5526-36
references: 19828632
references: Mol Cell Proteomics. 2009 May;8(5):971-85
references: 19164279
references: Nat Immunol. 2000 Nov;1(5):413-8
references: 11062501
references: Proteomics. 2005 Jan;5(1):4-15
references: 15602776
references: Keio J Med. 1996 Jun;45(2):100-8
references: 8683899
references: Proteomics Clin Appl. 2008 Mar;2(3):355-71
references: 21136839